PandaOmics is a cloud-based software platform that leverages artificial intelligence and bioinformatics techniques to identify therapeutic targets and biomarkers from multimodal omics and biomedical text data. The platform generates novel and repurposed hypotheses with desired properties and has been validated in both in vitro and in vivo studies. It is part of Insilico Medicine’s Pharma.ai drug discovery suite, which includes Chemistry42 for de novo small molecule generation and inClinico for predicting clinical trial success. PandaOmics offers a comprehensive data processing pipeline, enabling systematic searches for relevant datasets and providing a user-friendly interface for data exploration and analysis. Key features include dataset selection, sample group comparison, gene- and pathway-level analysis, meta-analysis, and indication prioritization. The platform integrates with robotic platforms for target validation and compound screening, streamlining the research process. Validation studies demonstrate high predictive power, with average fold enrichment of approximately 15, and successful application across various therapeutic areas. Case studies highlight its effectiveness in identifying therapeutic targets for aging-related diseases, ALS, and hepatocellular carcinoma, as well as in prioritizing targets associated with protein phase separation. PandaOmics plays a crucial role in the Pharma.AI ecosystem, working in tandem with other tools to accelerate drug discovery and development.PandaOmics is a cloud-based software platform that leverages artificial intelligence and bioinformatics techniques to identify therapeutic targets and biomarkers from multimodal omics and biomedical text data. The platform generates novel and repurposed hypotheses with desired properties and has been validated in both in vitro and in vivo studies. It is part of Insilico Medicine’s Pharma.ai drug discovery suite, which includes Chemistry42 for de novo small molecule generation and inClinico for predicting clinical trial success. PandaOmics offers a comprehensive data processing pipeline, enabling systematic searches for relevant datasets and providing a user-friendly interface for data exploration and analysis. Key features include dataset selection, sample group comparison, gene- and pathway-level analysis, meta-analysis, and indication prioritization. The platform integrates with robotic platforms for target validation and compound screening, streamlining the research process. Validation studies demonstrate high predictive power, with average fold enrichment of approximately 15, and successful application across various therapeutic areas. Case studies highlight its effectiveness in identifying therapeutic targets for aging-related diseases, ALS, and hepatocellular carcinoma, as well as in prioritizing targets associated with protein phase separation. PandaOmics plays a crucial role in the Pharma.AI ecosystem, working in tandem with other tools to accelerate drug discovery and development.